Current Challenges and Drug Delivery Updates in Vulvovaginal Candidiasis Treatment: A Comprehensive Review

Clicks: 2
ID: 313535
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #150 of 159 articles by views in medical mycology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 159 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
To provide a comprehensive summary of a decade (2014-2025) of high-quality research from Q1-Q3 journals on formulation development and improved drug-delivery methods for vulvovaginal candidiasis, addressing the limits of conventional antifungal therapy. A detailed narrative review was carried out using PubMed, Scopus, Springer, Wiley, Frontiers, ClinicalTrials.gov, and Google Scholar. To maintain scientific rigor, only the most relevant Q1-Q3 indexed publications were included. Studies published in the last eleven years have been evaluated for their relevance to vaginal drug delivery systems and anti-fungal formulations. Data were systematically retrieved and described in text and tables, with 203 formulation techniques given, including nanoparticles, vesicular carriers, mucoadhesive systems, thermosensitive gels, electrospun nanofibers, microneedles, and three-dimensional printed dosage forms. The key outcomes examined were vaginal retention, drug release behavior, mucosal penetration, antibiofilm activity, and antifungal efficacy. In comparison to conventional formulations, advanced drug-delivery systems displayed longer vaginal residence time, sustained drug release, and improved tissue penetration. Nanoparticle-based and mucoadhesive systems demonstrated increased antifungal effectiveness against both microbial and biofilm-associated Candida species, with absolute fungal clearance improvements ranging from 25 to 45% in preclinical applications. This review combines eleven years of formulation research, minimizing the need for readers to sift over fragmented literature. Major limitations included study design variability and a lack of long-term clinical data. This 11-year synthesis identifies improved drug-delivery technologies as promising patient-centered solutions for overcoming resistance, recurrence, and poor drug retention in VVC treatment. These drug delivery systems constitute an important step toward next-generation antifungal therapy and better clinical outcomes.
Reference Key
openalex_W7161054522 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shital Vikas Jadhav, Aparna Vijay Bhalerao, Zeeshan Nasiruddin Ansari
Journal medical mycology
Year 2026
DOI
10.1093/mmy/myag048
URL
https://doi.org/10.1093/mmy/myag048
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.